NO20090875L - Fusjonspeptid for inhibenng av interaksjon mellom neuronal NMDA-reseptor og NMDAR-mteragerende proteiner - Google Patents

Fusjonspeptid for inhibenng av interaksjon mellom neuronal NMDA-reseptor og NMDAR-mteragerende proteiner

Info

Publication number
NO20090875L
NO20090875L NO20090875A NO20090875A NO20090875L NO 20090875 L NO20090875 L NO 20090875L NO 20090875 A NO20090875 A NO 20090875A NO 20090875 A NO20090875 A NO 20090875A NO 20090875 L NO20090875 L NO 20090875L
Authority
NO
Norway
Prior art keywords
nmdar
fusion peptide
component
inhibiting interaction
nmda receptor
Prior art date
Application number
NO20090875A
Other languages
English (en)
Inventor
Thomas Meyer
Original Assignee
Xigen Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xigen Sa filed Critical Xigen Sa
Publication of NO20090875L publication Critical patent/NO20090875L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Den foreliggende oppfinnelsen tilveiebringer et fusjonspeptid som omfatter minst en komponent (1), hvori komponent (1) omfatter et transportpeptid og en komponent (II) valgt fra et peptid som inhiberer interaksjon mellom nevronal N-metyl-D-aspartatreseptor (NMDAR) og NMDAR-interagerende proteiner, hvori komponent (II) i sin helhet består av D-enantiomere aminosyrer. Den foreliggende oppfinnelsen tilveiebringer videre en farmasøytisk sammensetning i henhold til oppfinnelsen som omfatter fusjonspeptidet i henhold til oppfinnelsen og fremgangsmåter til å administrere disse så vel som sett og anvendelser som anvender fusjonspeptidet i henhold til oppfinnelsen.
NO20090875A 2006-07-31 2009-02-25 Fusjonspeptid for inhibenng av interaksjon mellom neuronal NMDA-reseptor og NMDAR-mteragerende proteiner NO20090875L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06015911A EP1884521A1 (en) 2006-07-31 2006-07-31 Fusion peptide for inhibiting interaction of neuronal NMDA receptor (NMDAR) and NMDAR interacting proteins
PCT/EP2007/006619 WO2008014917A1 (en) 2006-07-31 2007-07-25 Fusion peptide for inhibiting interaction of neuronal nmda receptor (nmdar) and nmdar interacting proteins

Publications (1)

Publication Number Publication Date
NO20090875L true NO20090875L (no) 2009-02-25

Family

ID=37084687

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090875A NO20090875L (no) 2006-07-31 2009-02-25 Fusjonspeptid for inhibenng av interaksjon mellom neuronal NMDA-reseptor og NMDAR-mteragerende proteiner

Country Status (15)

Country Link
US (1) US20090281036A1 (no)
EP (2) EP1884521A1 (no)
JP (1) JP2009545543A (no)
KR (1) KR20090033868A (no)
CN (1) CN101490081A (no)
AT (1) ATE509948T1 (no)
AU (1) AU2007280717A1 (no)
BR (1) BRPI0714783A2 (no)
CA (1) CA2653438A1 (no)
HR (1) HRP20080648A2 (no)
IL (1) IL195536A0 (no)
MX (1) MX2009001095A (no)
NO (1) NO20090875L (no)
RU (1) RU2009106710A (no)
WO (1) WO2008014917A1 (no)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5746468B2 (ja) * 2006-07-11 2015-07-08 ノノ インコーポレイテッド 発熱を伴う脳卒中を処置する方法および組成物
GB0804496D0 (en) * 2008-03-11 2008-04-16 Theryte Ltd Treating cancer
WO2009140416A2 (en) * 2008-05-16 2009-11-19 Arbor Vita Corporation Treatment for epilepsy
CN102202677A (zh) * 2008-09-03 2011-09-28 阿尔伯维塔公司 治疗疼痛的活性剂和方法
JP6005514B2 (ja) * 2009-06-10 2016-10-12 ノノ インコーポレイテッド 神経疾患の治療のためのモデル系及び治療計画
CA3018494C (en) 2009-06-10 2021-12-07 Nono Inc. Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
EP2616094B1 (en) 2010-08-12 2017-11-08 NoNO Inc. Treatment of penetrative injury to the brain
US9150618B2 (en) 2010-10-14 2015-10-06 Xigen Inflammation Ltd. Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
WO2012158624A2 (en) 2011-05-13 2012-11-22 The Board Of Trustees Of The Leland Stanford Junior University Inhibitors of mitochondrial fission and methods of use thereof
US10064910B2 (en) 2011-06-24 2018-09-04 Nono Inc. Combination therapy for ischemia
US9579358B2 (en) 2011-10-10 2017-02-28 Lancaster University Business Enterprises Limited Compositions for binding to amyloid proteins
KR102114490B1 (ko) * 2011-12-13 2020-05-25 노노 인코포레이티드 지주막하 출혈 및 허혈에 대한 치료법
US9241970B2 (en) 2011-12-13 2016-01-26 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
US10251935B2 (en) 2012-11-28 2019-04-09 Nono Inc. Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose
KR102166374B1 (ko) * 2012-11-28 2020-10-15 노노 인코포레이티드 Tat-nr2b9c의 동결건조된 제형
US20140296164A1 (en) * 2013-03-29 2014-10-02 Calista Therapeutics, Inc. Compositions and methods of use for cell targeted inhibitors of the Cystic Fibrosis transmembrane regulator associated ligand
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
CA2903275A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
ES2724932T3 (es) 2013-10-30 2019-09-17 Univ Western Australia Péptidos neuroprotectores
CN103804500B (zh) * 2014-01-22 2015-12-30 广州军区广州总医院 用于治疗慢性疼痛的多肽
AU2015226911B2 (en) * 2014-03-07 2018-03-01 The Arizona Board Of Regents On Behalf Of The University Of Arizona Non-narcotic CRMP2 peptides targeting sodium channels for chronic pain
CN103936838B (zh) * 2014-04-10 2015-10-28 武汉启瑞科技发展有限公司 小分子多肽TAT-p53DM及其在制备治疗或预防缺血性卒中药物中的应用
MX2016015457A (es) 2014-05-28 2017-06-30 Nono Inc Sal de cloruro de tat-nr2b9c.
EP3148568A4 (en) * 2014-05-28 2018-01-17 Nono Inc. Lyophilized formulation of tat-nr2b9c with acetylation scavenger
US20170253643A1 (en) * 2014-09-02 2017-09-07 Tokyo University Of Science Foundation Centrally-Acting Peptide Derivative, and Pharmaceutical Composition
CN104650242A (zh) * 2015-01-13 2015-05-27 河南科技大学 一种融合多肽及其制备方法和应用
AU2016348632B2 (en) 2015-11-06 2023-07-13 The Board Of Trustees Of The University Of Illinois Peptides and method for treatment of cardiac arrest
JP6818871B2 (ja) * 2016-04-27 2021-01-20 ▲拝▼西欧斯（北京）生物技▲術▼有限公司 興奮性神経毒性に関連した損傷の治療用ペプチド
WO2018085436A1 (en) * 2016-11-01 2018-05-11 Memorial Sloan Kettering Cancer Center Agents and methods for treating creb binding protein-dependent cancers
CN110049994B (zh) * 2016-12-08 2023-05-02 拜西欧斯（北京）生物技术有限公司 一种缀合物及其应用
EP3784261A4 (en) * 2017-04-02 2021-11-03 InterK Peptide Therapeutics Limited COMPOSITIONS AND METHODS FOR THE PREVENTION OR TREATMENT OF PAIN
BR112020000115A2 (pt) * 2017-07-05 2020-07-07 Biocells (Beijing) Biotech Co., Ltd. sais farmaceuticamente aceitáveis de polipeptídeos e uso dos mesmos
WO2019006692A1 (zh) * 2017-07-05 2019-01-10 拜西欧斯（北京）生物技术有限公司 用于治疗、改善或预防神经系统相关病症的化合物及其用途
CN112279921A (zh) 2019-07-11 2021-01-29 厦门大学 用于胞内递送分子的复合物
EP4086275A4 (en) 2019-12-31 2024-04-17 Xiamen University MULTIMERIZATION DELIVERY SYSTEM FOR INTRACELLULAR DELIVERY OF MOLECULES
AU2021206472A1 (en) * 2020-01-09 2022-08-18 Nono Inc. Plasmin-resistant peptides for treating stroke and related conditions
CN114539358B (zh) * 2020-11-19 2023-09-15 中国科学院大连化学物理研究所 一种多肽及制备方法与应用
CN112853559B (zh) * 2020-12-31 2021-10-08 盐城师范学院 一种基于环锭纺纱线质量的工序约束嵌套控制系统及方法
CN113735938A (zh) * 2021-07-30 2021-12-03 英纳氏(珠海)药业有限公司 一种神经保护多肽化合物及其应用
CN118359717A (zh) * 2023-01-18 2024-07-19 中国科学院脑科学与智能技术卓越创新中心 抗nmda受体自身免疫性脑炎新型抗体及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998023781A1 (en) * 1996-11-26 1998-06-04 Johns Hopkins University Ligand detection system and methods of use thereof
US7510824B2 (en) * 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
CA2505479A1 (en) * 2002-11-14 2004-06-03 Arbor Vita Corporation Molecular interactions in neurons

Also Published As

Publication number Publication date
KR20090033868A (ko) 2009-04-06
IL195536A0 (en) 2011-08-01
RU2009106710A (ru) 2010-09-10
WO2008014917A1 (en) 2008-02-07
EP2046821B1 (en) 2011-05-18
EP1884521A1 (en) 2008-02-06
CA2653438A1 (en) 2008-02-07
ATE509948T1 (de) 2011-06-15
AU2007280717A1 (en) 2008-02-07
BRPI0714783A2 (pt) 2013-07-30
HRP20080648A2 (en) 2009-02-28
MX2009001095A (es) 2009-02-10
EP2046821A1 (en) 2009-04-15
JP2009545543A (ja) 2009-12-24
CN101490081A (zh) 2009-07-22
US20090281036A1 (en) 2009-11-12

Similar Documents

Publication Publication Date Title
NO20090875L (no) Fusjonspeptid for inhibenng av interaksjon mellom neuronal NMDA-reseptor og NMDAR-mteragerende proteiner
ATE491349T1 (de) Neue nutrazeutika-zusammensetzungen
BRPI0809366B8 (pt) polipeptídeo substancialmente alfa-helicoidal, método para fabricação do mesmo, aminoácido e composição farmacêutica
RS50966B (sr) Agonisti pyy i njihova upotreba
IL195338A (en) An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use
EA200700210A1 (ru) ВАРИАНТЫ ОБЛАСТИ Fc
EP2617431A3 (en) Polypeptide inhibitors of HSP27 kinase and uses therefor
ATE526318T1 (de) Farnesoid-x-rezeptor-agonisten
WO2006097536A3 (en) Dimeric peptide agonists of the glp-1 receptor
NO20090047L (no) Anti-DLL4-antistoffer og fremgangsmater for anvendelse av disse
NO20080246L (no) Anti-IGF1R-antistofformuleringer
EA200802170A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
WO2008079995A3 (en) Conjugate of natriuretic peptide and antibody constant region
WO2006066024A8 (en) Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
EA200802128A1 (ru) Новые нутрицевтические композиции
BRPI0413644A (pt) métodos para separar as duas formas de um polipeptìdeo tendo uma única racemização de aminoácido, e para separar dois polipeptìdeos, produto de polipeptìdeo, e, composição farmacêutica
IL223077A0 (en) Novel as160-like protein, test systems, methods and uses involving it for the identification of diabetes type 2 therapeutics
WO2007022042A3 (en) Combinations comrising a protein kinase inhibitor being a pyrimidylaminobξnzamide compound and a hsp90 inhibitor such as 17-aag
WO2007047962A3 (en) Insecticides that target protein kinase a (pka)
BRPI0513715A (pt) veìculo para medicamentos para obtenção de biodisponibilidade oral
NZ601647A (en) Variant hhip1 protein and methods and uses thereof
WO2008100290A3 (en) Recombinant rhinovirus vectors
WO2007117665A3 (en) Derivatization-enhanced analysis of amino acids and peptides
AP2006003544A0 (en) Amino acids with affinity for the alpha2delta-protein.
WO2007110772A8 (en) Immunomodulating oligopeptides

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application